Investigator Sponsored Trials (IST)
Seeing the therapeutic potential of a more integrated approach to hematologic malignancies, Verastem Oncology is working to develop duvelisib into a new and impactful way to address the needs of patients with many blood cancers.
Verastem Oncology is committed to advancing the science and development of its product candidates to improve the lives of patients diagnosed with cancer in ways that are truly meaningful to them. We welcome collaboration with researchers and sponsoring institutions toward this shared goal.
To submit a research proposal, please complete and submit the following form to verastem-IST@verastem.com.